

Immunotherapy in GU Cancer

- 8:00-8:05 am **Welcome and Introduction**
Christopher Evans, MD, Allen Gao, MD
- 8:05-8:35 am **Overview of Immunotherapy in GU**
James Gulley, MD, NCI
- 8:35-8:55 am **Targeting Myeloid Derived Suppressor Cells in Urologic Cancers**
Timothy Ratliff, PhD, Purdue University
- 8:55-9:15 am **Engaging the immune system to combat prostate cancer**
Lauren Harshman, MD, Harvard University
- 9:15-9:30 am **Panel Discussion and Questions**
- 9:30-9:35 **Immunotherapy in Urothelial cancer**
Moderators: Timothy Ratliff, PhD, Sia Daneshmand, MD (USC)
- 9:35-9:55 am **Translational research to potentiate immunotherapy in urothelial cancer**
Chong-xian Pan, MD, PhD (UC Davis)
- 9:55-10:15 am **Immunotherapy in renal cell carcinoma: Current standing and future directions**
Matthew Campbell, MD (MD Anderson)
- 10:15-10:35 am **Refining Immunotherapy Combinations and Sequencing in Bladder Cancer**
Joaquim Bellmunt, MD (Dana-Farber Cancer Institute)
Joaquim_bellmunt@dfci.harvard.edu
- 10:35-10:50 am **Panel Discussion and Questions**
- 10:50-10:55 **Donald S. Coffey Lecture Introduction**
- 10:55-11:35 am **Donald S. Coffey Lecture:**
Lieping Chen, MD, PhD. Yale University
http://bbs.yale.edu/people/lieping_chen.profile

Dr. Chen's study established the foundation for the anti-PD-1/PD-L1 therapy for human cancer with contributions in both basic and translational research. In basic research, his laboratory co-discovered the PD-1/PD-L1 pathway and elucidated its functions. These findings include discovery of B7-H1 (PD-L1) molecule; its immune suppressive function as well as normal physiological functions. In translational research, his studies have singularly established the PD-1/PD-L1 pathway as target for cancer immunotherapy. These studies made the first link of the PD-L1/PD-1 pathway to cancer.

11:35-11:45 am

Questions

11:45 am

Adjourn

AUA ACCREDITATION INFORMATION

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this live activity for a maximum of **3.0 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for *AMA PRA Category 1 Credit™*.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual's relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty

Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

AUA PARTICIPANT INFORMATION & POLICIES

Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Consent to Use of Photographic Images: Attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA's use and distribution (both now and in the future) of the attendee's image or voice in photographs and electronic reproductions of such meetings and activities.

Audio, Video and Photographic Equipment: The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.

Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

Special Assistance/Dietary Needs: The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the registration desk.